Denver-based startup Intero Biosystems is scaling its GastroScreen technology, which uses lab-grown human organoids to replace traditional animal drug testing. With regulatory support from new FDA guidance, the company aims to move pharmaceutical trials toward human-relevant data. However, as an early-stage firm with modest revenue, its success depends on overcoming manufacturing hurdles and proving its models against established clinical data.
Pharmaceutical testing is undergoing a shift as companies look for ways to reduce dependence on animal models. Denver-based startup Intero Biosystems is attempting to lead this change with its GastroScreen technology, which uses lab-grown human intestinal organoids to replicate human biological responses to drugs, food, and chemicals. By using induced pluripotent stem cells, the company can convert blood samples into intestinal tissue, creating models that better mimic human anatomy than traditional cell cultures.
The business model revolves around selling these one-millimeter organoids to pharmaceutical and chemical firms. These clients use the models to test substances in healthy states or to simulate disease conditions. The company reported generating over $400,000 in revenue between late 2023 and the third quarter of 2024. While this shows early demand, the company remains in a growth phase, focusing on automating its manufacturing process to increase output from thousands to hundreds of thousands of units per batch.
A major tailwind for Intero and its competitors, such as Altis Biosystems and InSphero, is the change in regulatory guidance in the United States. New FDA policies regarding New Approach Methodologies now encourage the use of non-animal testing methods, provided they meet safety and efficacy benchmarks. This shift has widened the market for companies offering biological alternatives to animal trials, as drug developers seek faster and more accurate ways to predict human reactions.
Despite the potential, the company faces several operational risks. Transitioning from small-batch lab production to large-scale, automated manufacturing is a difficult challenge. Any failure to maintain the quality and consistency of these organoids at higher volumes could hurt adoption by pharmaceutical clients, who require strict, reproducible data for regulatory approvals. Furthermore, the company is in the middle of a three-part validation process. It has confirmed the structural integrity of its models and is now benchmarking them against compounds with known human effects. The final phase involves a direct comparison with existing clinical and animal data. Until this validation is complete and widely accepted by the industry, the potential for these organoids to fully replace animal models remains speculative.
Investors monitoring the biotech space should track Intero's progress in two key areas. First, the success of its automation efforts is critical to scaling operations and achieving a sustainable cost structure. Second, the upcoming validation results against clinical and animal data will determine whether the technology can earn the trust of large drug developers. As the company seeks to build unique biological datasets to support artificial intelligence models in drug discovery, the depth and accuracy of this data will likely be a primary factor in its long-term competitive position.